890 SENSITIVITY FACTORS ANALYSIS ON LOW DOSE KETOCONAZOLE PLUS PREDNISONE EFFECTIVE TREATMENT FOR CASTRATION RESISTANT PROSTATE CANCER
Guo-Wen Lin,Xu-Dong Yao,Ding-Wei Ye,Bo Dai,Yao Zhu
DOI: https://doi.org/10.1016/j.juro.2011.02.756
2011-01-01
Abstract:You have accessJournal of UrologyProstate Cancer: Advanced1 Apr 2011890 SENSITIVITY FACTORS ANALYSIS ON LOW DOSE KETOCONAZOLE PLUS PREDNISONE EFFECTIVE TREATMENT FOR CASTRATION RESISTANT PROSTATE CANCER Guo-Wen Lin, Xu-Dong Yao, Ding-Wei Ye, Bo Dai, and Yao Zhu Guo-Wen LinGuo-Wen Lin Shanghai, China, People's Republic of More articles by this author , Xu-Dong YaoXu-Dong Yao Shanghai, China, People's Republic of More articles by this author , Ding-Wei YeDing-Wei Ye Shanghai, China, People's Republic of More articles by this author , Bo DaiBo Dai Shanghai, China, People's Republic of More articles by this author , and Yao ZhuYao Zhu Shanghai, China, People's Republic of More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2011.02.756AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES To explore whether there were some predictors of low dose ketoconazole(LDK) effective treatment for castration resistant prostate cancer(CRPC). METHODS 71 patients with CRPC were eligible for this retrospective study. They underwent previous hormonal therapy failure and 14 patients had been given chemotherapy based on docetaxel. At the baseline, serum PSA, testosterone and hemoglobin were detected. Ketoconazole orally 200mg three times daily as LDK with prednisone 5mg twice a day was performed for these patients. PSA doubling time (PSADT) was applied, which was defined as PSA increase status before LDK therapy. The equation was PSADT= log(2)×ΔT/[log(PSAbaseline)-log(PSAfailue)], in which PSAbaseline indicated baseline PSA and PSAfailue was the first value of previous treatment failure, ΔT was the time interval between them. As response criteria of effective treatment, PSA response rate was defined as the percentage of patients with PSA decline>=50 compared PSAbaseline. Continuous variables were categorized in analysis by optimal cutoff which provided the greatest prognostic value by P value-based approach. A multivariate model was used to develop a nomogram predicting PSA response. RESULTS 22 (31.0%) patients were evaluable as PSA responders. Table 1 indicated baseline testosterone and PSADT as sensitivity predictors for LDK effective treatment in logistic regression models. PSA response rate was 55.6%(20/36) and 5.7%(2/35) for patients with baseline testosterone>=0.1ng/mL and <0.1ng/mL and was 44.8%(13/29) and 21.4%(9/42) for patients with PSADT>=2.0 month and <2.0 month. The area under the curve (AUC) of receiver operating characteristic for then were 0.791(95% confidence interval[CI] 0.682-0.900) and 0.632(95% CI 0.490-0.774). Figure 1 showed the result of nomogram. CONCLUSIONS The baseline testosterone>=0.1ng/mL and PSADT>=2.0 month may be new predictors for better outcome of LDK therapy for CRPC. © 2011 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 185Issue 4SApril 2011Page: e356-e357 Advertisement Copyright & Permissions© 2011 by American Urological Association Education and Research, Inc.Metrics Author Information Guo-Wen Lin Shanghai, China, People's Republic of More articles by this author Xu-Dong Yao Shanghai, China, People's Republic of More articles by this author Ding-Wei Ye Shanghai, China, People's Republic of More articles by this author Bo Dai Shanghai, China, People's Republic of More articles by this author Yao Zhu Shanghai, China, People's Republic of More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...